



FOR IMMEDIATE RELEASE

8 AUGUST 2006

ANGEL BIOTECHNOLOGY HOLDINGS PLC
(“Angel” or “the Company”)

Angel announces extension of GMP Stem cell contract

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce an extension to its GMP contract with ReNeuron Group plc, a leading player in the field of stem cell therapeutics. Terms of the contract have not been disclosed.

Angel has manufactured a cell bank to GMP for ReNeuron’s ReN005 adult stem cell line for Huntington’s disease; the original contract has been extended to undertake additional GMP process testing.

This contract extension further strengthens the relationship with ReNeuron which was founded when the companies joined forces in a consortium that was awarded a £2.2m, 3-year, grant by the UK Department of Trade and Industry (DTI) in January 2005. The consortium, led by ReNeuron, is undertaking a bioprocessing project entitled ‘Therapeutic Products from Human Stem Cells’ in which Angel is the manufacturing partner. Angel’s key role is to establish the capability to manufacture and scale-up stem cell technologies to GMP standards for clinical trials and for their application as therapeutic products.

Angel’s licenced facility in Edinburgh, specialising in the manufacture of cell based therapies, was utilised for the contracted GMP manufacturing work. The process testing will be performed at Angel’s Development Laboratories in its Cramlington facility.

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said: “Angel is delighted that the GMP stem cell bank contract has been successfully concluded and that ReNeuron has acknowledged Angel’s skills and capabilities in GMP manufacturing of stem cells by extending our working relationship with this additional process testing work. We look forward to further collaborations in the future, both on this contract as well as continuing to work with ReNeuron in other directions as part of the Stem Cell Consortium.”

Michael Hunt, Chief Executive Officer of ReNeuron, said: “We have been pleased with the level of service and expertise provided by Angel on the initial cell banking contract for ReN005, and are delighted to be extending our contract manufacturing relationship with Angel into the field of GMP process testing.”

For further information, please call:

Angel Biotechnology Holdings plc
Gordon Sherriff – COO

Tel 01670 591920
Tel 07951 057016

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and was admitted to trading on AIM in November 2005.

About ReNeuron Plc

ReNeuron is a leading, UK-based adult stem cell therapy business. The Company is applying its novel c-mycER^{TAM} stem cell platform technology in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs.

The Company's lead stem cell therapy, ReN001 for chronic stroke disability, is in late pre-clinical development. The Company plans to file for approval to commence initial clinical trials in stroke later this year, with trials commencing as soon as possible thereafter. The Company has also generated pre-clinical efficacy data with its ReN005 stem cell therapy for Huntington's disease, a rare, genetic and fatal neurodegenerative disorder which affects around 1 in 100,000 people. This programme is in pre-clinical development. In addition to these programmes, ReNeuron is developing stem cell therapies for Parkinson's disease, Type 1 diabetes and diseases of the retina.

The Company successfully completed its flotation on the London AIM market in August 2005. ReNeuron's shares are traded under the symbol RENE.L.

Further information on ReNeuron and its products can be found at www.reneuron.com.